Epinephrine Dose: Optimal Versus Standard Evaluation Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1250 participants.

Also called NCT03826524

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03826524
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT03826524. Randomized; triple masking; primary purpose treatment. Start 2023-05-24 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Epinephrine Dose: Optimal Versus Standard Evaluation Trial
Acronym
EpiDOSE
Condition
Cardiac Arrest, Out-Of-Hospital
Condition
Ventricular Tachycardia-Pulseless
Intervention (Drug)
Epinephrine
Lead sponsor
Unity Health Toronto (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)

Record details

Record id
cardio:ct-nct03826524
Content hash
ae2d73f6be7b52faf448b4975ed054e7d5008bd7283690fc0f92a3ff679d7b86